Yong Cheng

Dr. Yong Cheng received his B.S. degree in Biotechnology in 2002 and his Ph.D. degree in Microbiology in 2007 from Huazhong Agricultural University, China. In 2007, Dr. Cheng joined the University of Basel, Switzerland, with F. Hoffmann–La Roche Ltd Postdoctoral Fellowship. In 2011, Dr. Cheng then joined the Dr. Jeffrey Schorey’s lab at the University of Notre Dame, Indiana. Dr. Cheng’s previous study focused on the research understanding the mechanism of host-pathogen interactions in the context of mycobacterial infections, and novel antimycobacterial drug discovery in collaboration with the biopharmaceutical companies, Hsiri Therapeutics Inc and Shionogi & Co. His study also included the development of new anti-tuberculosis vaccines and diagnostic tools. In 2020, Dr. Cheng joined the Department of Biochemistry and Molecular Biology, Oklahoma State University. He is currently working on multiple projects understanding the interactions between Mycobacterium tuberculosis/non-tuberculous mycobacteria (NTM) and the host.